15. Netflix (NasdaqGS:NFLX)
> 3-yr. revenue chg.: 87.8%
> Latest annual revenue: $6.8 billion
Internet television network Netflix is one of America’s fastest growing companies. In its most recent fiscal year, the company reported revenue of $6.8 billion, up from $3.6 billion in 2012 — an 87.8% growth. More than 75 million Netflix users in 190 countries consume approximately 125 million hours of TV shows and movies daily. Netflix’s stock price rose to over $100 last summer, where it has remained roughly unchanged since.
The company’s 2015 annual profit of $122.6 million was down from $266.8 the year before. Netflix attributes the decline to increased costs from its investments in both overseas expansion and continued original content productions.
14. Illumina (NasdaqGS:ILMN)
> 3-yr. revenue chg.: 93.3%
> Latest annual revenue: $2.2 billion
Research outfit Illumina is known as one of the world’s largest genomic sequencing companies. In its most recent fiscal year, sales of Illumina’s proprietary technologies and instruments accounted for 27% of total revenue. Sales of consumables — materials and compounds the company sells mostly for use in DNA sequencing — accounted for 58%.
Illumina does not make drugs. However, the company works closely with pharmaceutical companies, which are well represented among America’s fastest growing companies. Like drugmakers, Illumina’s financial performance is partially dependent on the success of its research as well as whether the Food and Drug Administration approves certain products.
13. Biogen (NasdaqGS:BIIB)
> 3-yr. revenue chg.: 95.2%
> Latest annual revenue: $10.8 billion
Biotechnology company Biogen Inc. nearly doubled its revenue in the last three years, from $5.5 billion in fiscal 2013 to $10.8 billion in revenue in fiscal 2016. The company, which started in 1978, has since grown through a series of drug developments and corporate acquisitions to become one of the most profitable businesses in biotech. Biogen reported $3.5 billion in profit in fiscal 2015, up from $2.9 billion in fiscal 2014.
While much of Biogen’s revenue growth was organic, some share of its expansion was also the result of acquisition. The company acquired Convergence Pharmaceuticals for $675 million in 2015. Convergence increased Biogen’s portfolio of pain drugs.